Table 4.
End of treatment comparison of clinical and laboratory parameters across treatment groups
| Parameter | Therapeutic groups | Mean ± SD | 95% CI | P-value |
|---|---|---|---|---|
| Mean liver span (cm) | Miltefosine | 1.29 ± 1.57 | 0.94–1.64 | 0.3 |
| Combination therapy | 1.01 ± 1.73 | 0.58–1.44 | ||
| Centimeters of spleen palpable below the left costal margin | Miltefosine | 3.92 ± 2.43 | 3.37–4.47 | 0.1 |
| Combination therapy | 3.27 ± 2.7 | 2.6–3.93 | ||
| Mean hemoglobin (gm/dL) | Miltefosine | 9.31 ± 1.24 | 9.03–9.59 | < 0.001 |
| Combination therapy | 10.15 ± 1.55 | 9.77–10.54 | ||
| Mean total leukocyte count | Miltefosine | 3,663.97 ± 923.41 | 3,455.77–3,872.17 | < 0.001 |
| Combination therapy | 4,983.33 ± 1,379.69 | 4,644.16–5,322.51 | ||
| Mean erythrocyte sedimentation rate | Miltefosine | 61.96 ± 43.77 | 52.09–71.83 | 0.8 |
| Combination therapy | 60.8 ± 40.77 | 50.77–70.82 | ||
| Mean platelet count | Miltefosine | 170,333.33 ± 46,158.86 | 159,926.11–180,740.54 | < 0.001 |
| Combination therapy | 220,500 ± 71,676.24 | 202,879.77–238,120.22 | ||
| Mean total bilirubin (mg/dL) | Miltefosine | 0.81 ± 0.18 | 0.77–0.85 | 0.3 |
| Combination therapy | 0.76 ± 0.4 | 0.67–0.86 | ||
| Mean conjugated bilirubin (mg/dL) | Miltefosine | 0.38 ± 0.15 | 0.35–0.41 | 0.3 |
| Combination therapy | 0.33 ± 0.36 | 0.24–0.42 | ||
| Mean total protein (gm/dL) | Miltefosine | 8.66 ± 1.24 | 8.38–8.94 | < 0.001 |
| Combination therapy | 9.73 ± 1.68 | 9.32–10.15 | ||
| Mean albumin (gm/dL) | Miltefosine | 3.79 ± 0.92 | 3.59–4.01 | 0.01 |
| Combination therapy | 4.19 ± 1.03 | 3.93–4.44 | ||
| Mean serum glutamic oxaloacetic transaminase (IU/L) | Miltefosine | 53.43 ± 26.23 | 47.52–59.35 | 0.5 |
| Combination therapy | 57.19 ± 53.38 | 44.07–70.32 | ||
| Mean serum glutamic pyruvic transaminase (IU/L) | Miltefosine | 47.73 ± 37.42 | 39.29–56.16 | 0.7 |
| Combination therapy | 45.12 ± 38.37 | 35.68–54.55 | ||
| Mean urea (mg/dL) | Miltefosine | 36.19 ± 30.82 | 29.24–43.14 | 0.2 |
| Combination therapy | 30.51 ± 20.85 | 25.38–35.64 | ||
| Mean creatinine (mg/dL) | Miltefosine | 1.06 ± 0.47 | 0.95–1.16 | 0.3 |
| Combination therapy | 0.97 ± 0.51 | 0.84–1.1 | ||
| Mean serum sodium (meq/L) | Miltefosine | 137.83 ± 4.4 | 136.84–138.82 | 0.8 |
| Combination therapy | 137.96 ± 4.39 | 136.88–139.05 | ||
| Mean serum potassium (meq/L) | Miltefosine | 4.14 ± 0.38 | 4.05–4.22 | 0.008 |
| Combination therapy | 3.98 ± 0.309 | 3.91–4.05 |